Maccario Helene, Perera Nevin M, Davidson Lindsay, Downes C Peter, Leslie Nick R
Division of Molecular Physiology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Biochem J. 2007 Aug 1;405(3):439-44. doi: 10.1042/BJ20061837.
Although PTEN (phosphatase and tensin homologue deleted on chromosome 10) is one of the most commonly mutated tumour suppressors in human cancers, loss of PTEN expression in the absence of mutation appears to occur in an even greater number of tumours. PTEN is phosphorylated in vitro on Thr366 and Ser370 by GSK3 (glycogen synthase kinase 3) and CK2 (casein kinase 2) respectively, and specific inhibitors of these kinases block these phosphorylation events in cultured cells. Although mutation of these phosphorylation sites did not alter the phosphatase activity of PTEN in vitro or in cells, blocking phosphorylation of Thr366 by either mutation or GSK3 inhibition in glioblastoma cell lines led to a stabilization of the PTEN protein. Our data support a model in which the phosphorylation of Thr366 plays a role in destabilizing the PTEN protein.
尽管PTEN(第10号染色体缺失的磷酸酶及张力蛋白同源物)是人类癌症中最常发生突变的肿瘤抑制因子之一,但在没有突变的情况下,PTEN表达缺失似乎在更多肿瘤中出现。PTEN在体外分别被糖原合酶激酶3(GSK3)和酪蛋白激酶2(CK2)磷酸化在苏氨酸366和丝氨酸370位点,这些激酶的特异性抑制剂可在培养细胞中阻断这些磷酸化事件。尽管这些磷酸化位点的突变在体外或细胞中并未改变PTEN的磷酸酶活性,但在胶质母细胞瘤细胞系中,通过突变或抑制GSK3阻断苏氨酸366的磷酸化会导致PTEN蛋白的稳定。我们的数据支持一种模型,即苏氨酸366的磷酸化在使PTEN蛋白不稳定中起作用。